76 related articles for article (PubMed ID: 24262813)
1. Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial.
Mataix-Cols D; Turner C; Monzani B; Isomura K; Murphy C; Krebs G; Heyman I
Br J Psychiatry; 2014 Jan; 204(1):77-8. PubMed ID: 24262813
[TBL] [Abstract][Full Text] [Related]
2. D-cycloserine combined with cue exposure therapy fails to attenuate subjective and physiological craving in cocaine dependence.
Santa Ana EJ; Prisciandaro JJ; Saladin ME; McRae-Clark AL; Shaftman SR; Nietert PJ; Brady KT
Am J Addict; 2015 Apr; 24(3):217-224. PubMed ID: 25808169
[TBL] [Abstract][Full Text] [Related]
3. D-cycloserine-augmented one-session treatment of specific phobias in children and adolescents.
Farrell LJ; Waters AM; Oar EL; Tiralongo E; Garbharran V; Alston-Knox C; McConnell H; Collings N; Zimmer-Gembeck M; Donovan CL; Testa C; Storch EA; Ollendick TH
Brain Behav; 2018 Jun; 8(6):e00984. PubMed ID: 30106248
[TBL] [Abstract][Full Text] [Related]
4. A randomized placebo-controlled pilot study of the efficacy and safety of D-cycloserine in people with chronic back pain.
Schnitzer TJ; Torbey S; Herrmann K; Kaushal G; Yeasted R; Vania Apkarian A
Mol Pain; 2016; 12():. PubMed ID: 27852965
[TBL] [Abstract][Full Text] [Related]
5. Human perceptual learning is delayed by the N-methyl-D-aspartate receptor partial agonist D-cycloserine.
Dempsey-Jones H; Steudte-Schmiedgen S; Browning M; Makin TR; Woud ML; Harmer CJ; Margraf J; Reinecke A
J Psychopharmacol; 2021 Mar; 35(3):253-264. PubMed ID: 33570017
[TBL] [Abstract][Full Text] [Related]
6. D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: A meta-analysis.
Bürkner PC; Bittner N; Holling H; Buhlmann U
PLoS One; 2017; 12(3):e0173660. PubMed ID: 28282427
[TBL] [Abstract][Full Text] [Related]
7. A high-throughput clinical assay for testing drug facilitation of exposure therapy.
Rodebaugh TL; Levinson CA; Lenze EJ
Depress Anxiety; 2013 Jul; 30(7):631-7. PubMed ID: 23283838
[TBL] [Abstract][Full Text] [Related]
8. A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder.
Urbano M; Okwara L; Manser P; Hartmann K; Herndon A; Deutsch SI
Clin Neuropharmacol; 2014; 37(3):69-72. PubMed ID: 24824660
[TBL] [Abstract][Full Text] [Related]
9. Examining the efficacy of d-cycloserine to augment therapeutic learning in depression.
Otto MW; Lee J; Hofmann SG; Hearon BA; Smits JA; Rosenfield D; Fava M; Wright JH
Contemp Clin Trials; 2016 May; 48():146-52. PubMed ID: 27094721
[TBL] [Abstract][Full Text] [Related]
10. Cognitive-Behavioral Therapy Enhancement Strategies.
Tolin DF; Lord KA; Knowles KA
Psychiatr Clin North Am; 2024 Jun; 47(2):355-365. PubMed ID: 38724125
[TBL] [Abstract][Full Text] [Related]
11. Advances in the treatment of pediatric obsessive-compulsive d-cycloserine with exposure and response prevention.
McGuire JF; Lewin AB; Geller DA; Brown A; Ramsey K; Mutch J; Mittelman A; Micco J; Jordan C; Wilhelm S; Murphy TK; Small BJ; Storch EA
Neuropsychiatry (London); 2012 Aug; 2(4):. PubMed ID: 24174993
[TBL] [Abstract][Full Text] [Related]
12. The Future of D-Cycloserine and Other Cognitive Modifiers in Obsessive-Compulsive and Related Disorders.
Sulkowski ML; Geller DA; Lewin AB; Murphy TK; Mittelman A; Brown A; Storch EA
Curr Psychiatry Rev; 2014; 10(4):317-324. PubMed ID: 25383074
[TBL] [Abstract][Full Text] [Related]
13. D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders.
Hofmann SG; Wu JQ; Boettcher H
Biol Mood Anxiety Disord; 2013 Jun; 3(1):11. PubMed ID: 23768232
[TBL] [Abstract][Full Text] [Related]
14. Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis.
Rodrigues H; Figueira I; Lopes A; Gonçalves R; Mendlowicz MV; Coutinho ES; Ventura P
PLoS One; 2014; 9(7):e93519. PubMed ID: 24991926
[TBL] [Abstract][Full Text] [Related]
15. Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder.
McGuire JF; Lewin AB; Storch EA
Expert Rev Neurother; 2014 Aug; 14(8):893-910. PubMed ID: 24972729
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans.
Rothbaum BO; Price M; Jovanovic T; Norrholm SD; Gerardi M; Dunlop B; Davis M; Bradley B; Duncan EJ; Rizzo A; Ressler KJ
Am J Psychiatry; 2014 Jun; 171(6):640-8. PubMed ID: 24743802
[TBL] [Abstract][Full Text] [Related]
17. Telephone cognitive-behavioral therapy for adolescents with obsessive-compulsive disorder: a randomized controlled non-inferiority trial.
Turner CM; Mataix-Cols D; Lovell K; Krebs G; Lang K; Byford S; Heyman I
J Am Acad Child Adolesc Psychiatry; 2014 Dec; 53(12):1298-1307.e2. PubMed ID: 25457928
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis of the effects of long-term antibiotic use on cognitive outcomes.
Ye Y; Tong HYK; Chong WH; Li Z; Tam PKH; Baptista-Hon DT; Monteiro O
Sci Rep; 2024 Feb; 14(1):4026. PubMed ID: 38369574
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness of exposure and response prevention combined with pharmacotherapy for obsessive-compulsive disorder: A systematic review and meta-analysis.
Mao L; Hu M; Luo L; Wu Y; Lu Z; Zou J
Front Psychiatry; 2022; 13():973838. PubMed ID: 36186855
[TBL] [Abstract][Full Text] [Related]
20. Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects?
Maraone A; Tarsitani L; Pinucci I; Pasquini M
World J Psychiatry; 2021 Sep; 11(9):568-580. PubMed ID: 34631461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
